Visiotact

Visiotact Pharma is a French pharmaceutical laboratory specialized in the development and commercialization of ophthalmic products, based at the Institut de la Vision in Paris. Founded in 2007, the company offers a comprehensive range of eye health solutions, including dietary supplements such as Dualretinal and medical devices like Lacrymax Sensitive. The company focuses on addressing major ophthalmic pathologies, including age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma. By leveraging its location within a leading European eye research center, Visiotact Pharma bridges the gap between clinical research and commercial eye care, developing both preventive and therapeutic treatments. Its research portfolio also extends into innovative areas such as LIN28 inhibition for oncology and novel prostaglandin derivatives for intraocular pressure management.